Skip to main content
SpringerLink
Log in

Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents againstHelicobacter pylori

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The activities of various types of antiulcer agents againstHelicobacter pylori strains were determined by an agar dilution method. Among the compounds tested, benzimidazole proton pump inhibitors were found to have significant activity against this organism. The activity of lansoprazole was fourfold more potent than that of omeprazole and bismuth subsalicylate, with MICs ranging from 1.56 to 25 µg/ml. Exposure ofHelicobacter pylori to lansoprazole led to an extensive loss of viability as well as suppression of virulence factors such as motility, adhesiveness to epithelial cells and urease activity. The combination of lansoprazole with antimicrobial agents such as penicillins, cephalosporins, macrolides, tetracyclines, aminoglycosides, quinolones, metronidazole and bismuth subsalicylate generally had an additive effect on inhibition ofHelicobacter pylori growth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Warren JR, Marshall BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, i: 1273–1275.

    Google Scholar 

  2. Blaser MJ: GastricCampylobacter-like organisms, gastritis and peptic ulcer disease. Gastroenterology 1987, 93: 371–383.

    PubMed  Google Scholar 

  3. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow CR: Prospective double-blind trial of duodenal ulcer relapse after eradication ofCampylobacter pylori. Lancet 1988, ii: 1437–1442.

    Google Scholar 

  4. Goodwin CS, Blake P, Blincow E: The minimum inhibitory and bactericidal concentrations of antibiotics and antiulcer agents againstCampylobacter pyloridis. Journal of Antimicrobial Chemotherapy 1986, 17: 309–314.

    PubMed  Google Scholar 

  5. McNulty CAM, Dent JC: Susceptibility of clinical isolates ofCampylobacter pylori to twenty-one antimicrobial agents. European Journal of Clinical Microbiology & Infectious Diseases 1988, 7: 566–569.

    Google Scholar 

  6. Garcia-Rodriguez JA, Garcia-Sanchez JE, Garcia-Garcia MI, Garcia-Sanchez E, Munoz-Bellido JL: In vitro activities of new oral β-lactams and macrolides againstCampylobacter pylori. Antimicrobial Agents and Chemotherapy 1989, 33: 1650–1651.

    PubMed  Google Scholar 

  7. Westblom TU, Gudipati S, Midkiff BR: In vitro susceptibility ofHelicobacter pylori to the new oral cephalosporins, cefpodoxime, ceftibuten and cefixime. European Journal of Clinical Microbiology & Infectious Diseases 1990, 9: 691–693.

    Google Scholar 

  8. von Recklinghausen G, Maio CD, Ansorg R: Activity of antibiotics and azole antimycotics againstHelicobacter pylori. Zentralblatt für Bakteriologie 1993, 280: 279–285.

    Google Scholar 

  9. Suerbaum S, Leying H, Klemm K, Opferkuch W: Antibacterial activity of pantoprazole and omeprazole againstHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 92–93.

    Google Scholar 

  10. Armstrong JA, Wee SH, Goodwin CS, Wilson DH: Response ofCampylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro — an ultrastructural study. Journal of Medical Microbiology 1987, 24: 343–350.

    PubMed  Google Scholar 

  11. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB: Susceptibility ofCampylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 1988, 22: 631–636.

    PubMed  Google Scholar 

  12. Lambert T, Megraud F, Gerbaud G, Couvalin P: Susceptibility ofCampylobacter pyloridis to 20 antimicrobial agents. Antimicrobial Agents and Chemotherapy 1986, 30: 510–511.

    PubMed  Google Scholar 

  13. McNulty CAM, Dent J, Wise R: Susceptibility of clinical isolates ofCampylobacter pyloridis to 11 antimicrobial agents. Antimicrobial Agents and Chemotherapy 1985, 28: 837–838.

    PubMed  Google Scholar 

  14. Shungu DL, Nalin DR, Gilman RH, Gadebusch HH, Cerami AT, Gill C, Weissberger B: Comparative susceptibilities ofCampylobacter pylori to norfloxacin and other agents. Antimicrobial Agents and Chemotherapy 1987, 31: 949–950.

    PubMed  Google Scholar 

  15. Simor AE, Ferro S, Low DE: Comparative in vitro activities of six new fluoroquinolone and other oral antimicrobial agents againstCampylobacter pylori. Antimicrobial Agents and Chemotherapy 1989, 33: 108–109.

    PubMed  Google Scholar 

  16. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A: Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity againstHelicobacter pylori. Antimicrobial Agents and Chemotherapy 1991, 35: 490–496.

    PubMed  Google Scholar 

  17. Axon ATR:Helicobacter pylori therapy: effect on peptic ulcer disease. Journal of Gastroenterology and Hepatology 1991, 6: 131–137.

    PubMed  Google Scholar 

  18. Penner JL:Campylobacter, Helicobacter, and related spiral bacteria. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1991, p. 402–409.

    Google Scholar 

  19. Krogstad DJ, Moellering RC: Antimicrobial combinations. In: Lorian V (ed): Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, 1986, p. 537–595.

    Google Scholar 

  20. McNulty CAM, Dent JC, Uff JS, Gear MWL, Wilkinson SP: Detection ofCampylobacter pylori by the biopsy urease test: an assessment in 1445 patients. Gut 1989, 30: 1058–1062.

    PubMed  Google Scholar 

  21. Lingwood CA, Law H, Pellizani A: Gastric glycerolipid as a receptor forCampylobacter pylori. Lancet 1991, 337: 1486.

    Google Scholar 

  22. Megraud F, Boyanova L, Lamouliatte H: Activity of lansoprazole againstHelicobacter pylori. Lancet 1991, 337: 1486.

    Google Scholar 

  23. Hazell SL, Lee A, Brady L, Hennessy W:Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. Journal of Infectious Diseases 1986, 153: 658–663.

    PubMed  Google Scholar 

  24. Eaton KA, Morgan DR, Krakowka S: Motility as a factor in the colonization of gnotobiotic piglets byHelicobacter pylori. Journal of Medical Microbiology 1992, 37: 123–127.

    PubMed  Google Scholar 

  25. Lingwood CA, Huesca M, Kuksis A: The glycerolipid receptor forHelicobacter pylori (and exoenzyme S) is phosphatidylethanolamine. Infection and Immunity 1992, 60: 2470–2474.

    PubMed  Google Scholar 

  26. Casselli M, Figura N, Trevisani L, Pazzi P, Guglielmetti, P: Patterns of physical modes of contact betweenCampylobacter pylori and gastric epithelium: implications about the bacterial pathogenicity. American Journal of Gastroenterology 1989, 84: 511–513.

    PubMed  Google Scholar 

  27. Pérez-Pérez GI, Olivares AZ, Cover TL, Blaser MJ: Characteristics ofHelicobacter pylori variants selected for urease deficiency. Infection and Immunity 1992, 60: 3658–3663.

    PubMed  Google Scholar 

  28. Eaton KA, Brooks CL, Morgan DR, Krakowka S: Essential role of urease in pathogenesis of gastritis induced byHelicobacter pylori in gnotobiotic piglet. Infection and Immunity 1991, 59: 2470–2475.

    PubMed  Google Scholar 

  29. Mainguet P, Delmee M, Debongnie JC: Omeprazole,Campylobacter pylori, and duodenal ulcer. Lancet 1989, ii: 389–390.

    Google Scholar 

  30. Biasco G, Miglioli M, Barbara L, Corinaldesi R, Febo GD: Omeprazole,Helicobacter pylori, gastritis, and duodenal ulcer. Lancet 1989, ii: 1403.

    Google Scholar 

  31. Hui WM, Lam SK, Ho J, Lai CL, Lok ASF, Lau WY, Branicki FJ: Effect of omeprazole on duodenal ulcer-associated antral gastritis andHelicobacter pylori. Digestive Diseases and Sciences 1991, 36: 577–582.

    PubMed  Google Scholar 

  32. Unge P, Ekström P: Effect of combination therapy with omeprazole and an antibiotic onHelicobacter pylori and duodenal ulcer disease. Scandinavian Journal of Gastroenterology 1993, 28, Supplement 196: 17–18.

    Google Scholar 

  33. Logan RPH, Gummett PA, Hegarty BT, Walker MM, Baron JH, Misiewicz JJ: Clarithromycin and omeprazole forHelicobacter pylori. Lancet 1992, 340: 239.

    PubMed  Google Scholar 

  34. Bayerdörffer E, Mannes GA, Sommer A, Höchter W, Weingart J, Hatz R, Lehn N, Ruckdeschel G, Dirschedl P, Stolte M: High dose omeprazole treatment combined with amoxicillin eradicatesHelicobacter pylori. European Journal of Gastroenterology & Hepatology 1992, 4: 697–702.

    Google Scholar 

  35. Labenz J, Gyenes E, Rühl GH, Börsch G: Amoxicillin plus omeprazole versus triple therapy for eradication ofHelicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993, 34: 1167–1170.

    PubMed  Google Scholar 

  36. McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R:Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. British Medical Journal 1986, 293: 645–649.

    PubMed  Google Scholar 

  37. Unge P, Gnarpe H: Pharmacokinetic, bacteriological and clinical aspects of the use of doxycycline in patients with active duodenal ulcer associated withCampylobacter pylori. Scandinavian Journal of Infectious Diseases 1988, Supplement 53: 70–73.

    Google Scholar 

  38. Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, Bruck C: Treatment failure of ofloxacin inCampylobacter pylori infection. Lancet 1987, i: 1096.

    Google Scholar 

  39. Stone JW, Wise R, Donovan IA, Gearty J: Failure of ciprofloxacin to eradicateCampylobacter pylori from the stomach. Journal of Antimicrobial Chemotherapy 1988, 22: 92–93.

    PubMed  Google Scholar 

  40. Mertens JCC, Dekker W, Ligtvoet EEJ, Blok P: Treatment failure of norfloxacin againstCampylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrobial Agents and Chemotherapy 1989, 33: 256–257.

    PubMed  Google Scholar 

  41. Graham DY, Lew GM, Malaty HM, Evans DJ, Klein PD, Alpert LC, Genta RM: Factors influencing the eradication ofHelicobacter pylori with triple therapy. Gastroenterology 1992, 102: 493–496.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Research Laboratories III, Pharmaceutical Research Division, Takeda Chemical Industries Ltd., 17-85, Juso-Honmachi, 2-Chome, 532, Yodogawa-ku Osaka, Japan

    M. Nakao, M. Tada, K. Tsuchimori & M. Uekata

Authors
  1. M. Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Tsuchimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Uekata
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakao, M., Tada, M., Tsuchimori, K. et al. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents againstHelicobacter pylori . Eur. J. Clin. Microbiol. Infect. Dis. 14, 391–399 (1995). https://doi.org/10.1007/BF02114894

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02114894

Keywords

Search

Navigation